Skip to main content
. 2017 Nov 3;7(11):e017387. doi: 10.1136/bmjopen-2017-017387

Table 2.

Details of treatment

Parameter All GBM mEHT±SAT Combination treatment ddTMZ+mEHT LD-mEHT HD-mEHT HD-mEHT
<50 years
(1) (2) (3) (4) (5) (6) (7)
Value % Value % Value % Value % Value % Value % Value %
Time to first mEHT since diagnosis (months)
 Mean 12.1±1.6 11.2±2.3 12.3±1.9 12.9±2.1 13.3±2.4 11.5±2.0 12.7±4.2
 Median 8.5 8.0 9.3 9.5 9.9 8.2 5.9
 Range 0.2–94.2 2.3–44.1 0.2–94.2 0.2–94.2 1.6–49.1 0.2–94.2 1.0–94.2
 95% CI 6.7 to 10.6 6.1 to 15.2 5.8 to 10.7 5.9 to 10.7 6.1 to 11.6 5.1 to 10.0 4.1 to 10.0
 Earliest mEHT 01 March 2001 07 May 2001 01 March 2001 01 March 2001 07 June 2001 01 March 2001 01 March 2001
 Latest mEHT 20 May 2005 19 May 2005 20 May 2005 20 May 2005 28 April 2005 20 May 2005 20 May 2005
Treatment combinations
 mEHT+CRT+SAT 2 3% 0 0% 2 3% 0 0% 0 0% 2 4% 0 0%
 mEHT+chemoradiation 1 1% 0 0% 1 2% 0 0% 0 0% 1 2% 1 4%
 mEHT+chemotherapy+SAT 43 57% 0 0% 43 74% 43 80% 12 50% 31 60% 13 57%
 mEHT+radiation+SAT 1 1% 0 0% 1 2% 0 0% 0 0% 1 2% 1 4%
 mEHT+chemotherapy 11 14% 0 0% 11 19% 11 20% 6 25% 5 10% 3 13%
 mEHT+SAT 13 17% 13 72% 0 0% 0 0% 4 17% 9 17% 5 22%
 mEHT only 5 7% 5 28% 0 0% 0 0% 2 8% 3 6% 0 0%
Treatment by modality
 Radiation total 4 5% 0 0% 4 7% 0 0% 0 0% 4 8% 2 9%
 SAT total 59 78% 13 72% 46 79% 43 80% 16 67% 43 83% 19 83%
Chemotherapy total
 NOP 57 75% 0 0% 57 98% 54 100% 18 75% 39 75% 17 74%
 No. of cycles 89 0 89 84 18 71 32
 Mean 1.5±0.1 0 1.6±0.1 1.6±0.1 1.0±0.0 1.8±0.1 1.8±0.2
 Median 1.0 1.0 1.0 1.0 1.0 1.5 2.0
 Range 1.0–5.0 1.0–3.0 1.0–5.0 1.0–5.0 1.0–1.0 1.0–5.0 1.0–5.0
 95% CI 1.0 to 1.0 1.0 to 2.0 1.0 to 1.0 1.0 to 1.0 1.0 to 1.0 1.0 to 2.0 1.0 to 2.0
mEHT total
 NOP 76 100% 18 100% 58 100% 54 100% 24 100% 52 100% 23 100%
 No. of sessions 1367 292 1075 995 169 1198 545
 Mean 18.0±0.3 16.2±0.6 18.5±0.4 18.4±0.4 7.0±0.1 23.0±0.4 23.7±0.6
 Median 14.0 13.5 14.0 14.0 7.0 18.0 23.0
 Range 3.0–65.0 4.0–43.0 3.0–65.0 3.0–65.0 3.0–9.0 10.0–65.0 10.0–65.0
 95% CI 11.0 to 16.0 7.0 to 23.0 11.0 to 17.0 10.0 to 17.0 6.0 to 9.0 15.0 to 26.0 15.0 to 27.0
 Low-dose mEHT 24 32% 6 33% 18 31% 18 33% 24 100% 0 0% 0 0%
Time of treatment (months)
 Mean 2.5±0.4 1.6±0.4 2.8±0.5 2.7±0.6 0.5±0.0 3.4±0.6 3.4±0.7
 Median 1.1 1.0 1.1 1.1 0.5 1.9 1.9
 Range 0.0–26.4 0.2–6.4 0.0–26.4 0.0–26.4 0.0–0.8 0.2–26.4 0.5–12.2
 95% CI 0.8 to 1.5 0.5 to 2.1 0.8 to 1.6 0.8 to 1.6 0.4 to 0.6 1.2 to 2.8 1.2 to 4.6
 p Value (t-test) 0.233 0.001
 Terminated (NOP) 9 12% 1 6% 8 14% 8 15% 9 38% 0 0% 0 0%
 p Value (χ2) 0.35 <0.0001 0.085*

*Versus all GBM sample.

ddTMZ, dose-dense temozolomide; GBM, glioblastoma; HD, high dose; LD, low dose; mEHT, modulated electrohyperthermia; NOP, no. of patients; SAT, supportive and alternative treatments.